Logo image of FNCH

FINCH THERAPEUTICS GROUP INC (FNCH) Stock Fundamental Analysis

NASDAQ:FNCH - Nasdaq - US31773D2009 - Common Stock - Currency: USD

1.8  -0.18 (-9.09%)

After market: 1.8001 +0 (+0.01%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to FNCH. FNCH was compared to 551 industry peers in the Biotechnology industry. The financial health of FNCH is average, but there are quite some concerns on its profitability. FNCH has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

FNCH had negative earnings in the past year.
In the past year FNCH has reported a negative cash flow from operations.
In the past 5 years FNCH always reported negative net income.
In the past 5 years FNCH always reported negative operating cash flow.
FNCH Yearly Net Income VS EBIT VS OCF VS FCFFNCH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of FNCH (-32.51%) is better than 67.18% of its industry peers.
Looking at the Return On Equity, with a value of -85.55%, FNCH is in line with its industry, outperforming 48.19% of the companies in the same industry.
Industry RankSector Rank
ROA -32.51%
ROE -85.55%
ROIC N/A
ROA(3y)-77.06%
ROA(5y)-55%
ROE(3y)-158.4%
ROE(5y)-105.73%
ROIC(3y)N/A
ROIC(5y)N/A
FNCH Yearly ROA, ROE, ROICFNCH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

FNCH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FNCH Yearly Profit, Operating, Gross MarginsFNCH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -20K -40K -60K

More info and screens

6

2. Health

2.1 Basic Checks

FNCH does not have a ROIC to compare to the WACC, probably because it is not profitable.
FNCH has more shares outstanding than it did 1 year ago.
There is no outstanding debt for FNCH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FNCH Yearly Shares OutstandingFNCH Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 500K 1M 1.5M
FNCH Yearly Total Debt VS Total AssetsFNCH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -10.91, we must say that FNCH is in the distress zone and has some risk of bankruptcy.
FNCH has a Altman-Z score of -10.91. This is in the lower half of the industry: FNCH underperforms 78.76% of its industry peers.
FNCH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.91
ROIC/WACCN/A
WACC4.16%
FNCH Yearly LT Debt VS Equity VS FCFFNCH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M 150M 200M

2.3 Liquidity

FNCH has a Current Ratio of 6.05. This indicates that FNCH is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of FNCH (6.05) is better than 60.79% of its industry peers.
FNCH has a Quick Ratio of 6.05. This indicates that FNCH is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of FNCH (6.05) is better than 61.14% of its industry peers.
Industry RankSector Rank
Current Ratio 6.05
Quick Ratio 6.05
FNCH Yearly Current Assets VS Current LiabilitesFNCH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 89.38% over the past year.
The Revenue for FNCH has decreased by -100.00% in the past year. This is quite bad
The Revenue for FNCH have been decreasing by -75.98% on average. This is quite bad
EPS 1Y (TTM)89.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.8%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-75.98%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue is expected to grow by 507.50% on average over the next years. This is a very strong growth
EPS Next Y45.96%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y2874.9%
Revenue Next 3Y1411.62%
Revenue Next 5Y507.5%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FNCH Yearly Revenue VS EstimatesFNCH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
FNCH Yearly EPS VS EstimatesFNCH Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FNCH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FNCH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FNCH Price Earnings VS Forward Price EarningsFNCH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FNCH Per share dataFNCH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FNCH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FINCH THERAPEUTICS GROUP INC

NASDAQ:FNCH (5/24/2024, 8:00:00 PM)

After market: 1.8001 +0 (+0.01%)

1.8

-0.18 (-9.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-10 2023-08-10/bmo
Earnings (Next)N/A N/A
Inst Owners0.02%
Inst Owner Change0%
Ins Owners991.12%
Ins Owner Change0%
Market Cap2.90M
Analysts82.86
Price Target91.8 (5000%)
Short Float %0.01%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.15
P/tB 0.15
EV/EBITDA N/A
EPS(TTM)-10.15
EYN/A
EPS(NY)-21
Fwd EYN/A
FCF(TTM)-13.96
FCFYN/A
OCF(TTM)-13.97
OCFYN/A
SpS0
BVpS11.82
TBVpS11.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.51%
ROE -85.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-77.06%
ROA(5y)-55%
ROE(3y)-158.4%
ROE(5y)-105.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.18%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.05
Quick Ratio 6.05
Altman-Z -10.91
F-Score3
WACC4.16%
ROIC/WACCN/A
Cap/Depr(3y)244.78%
Cap/Depr(5y)255.54%
Cap/Sales(3y)113.24%
Cap/Sales(5y)76.75%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.8%
EPS Next Y45.96%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3Y-75.98%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y2874.9%
Revenue Next 3Y1411.62%
Revenue Next 5Y507.5%
EBIT growth 1Y73.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.49%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y73.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y71.01%
OCF growth 3YN/A
OCF growth 5YN/A